安必平发布业绩快报，2025年度实现营业总收入3.47亿元，同比下降26.24%；净利润亏损4497.17万 元，上年同期净利润为2129.13万元。报告期内，国家集采政策全面落地实施，公司HPV产品线售价同 比大幅下降，导致该业务收入减少约4650万元。 ...

东方生物发布业绩快报，2025年度公司实现营业总收入9.59亿元，比上年度增长15.83%；归属于母公司 所有者的净利润-5.64亿元，比上年度下降6.54%。本年度公司主营业务保持稳健的发展，但因各产业技 术平台战略发展，整体培育期间持续投入较大，汇兑损失及利息收入对利润的贡献减少，同时计提资产 相关折旧摊销费用，计提部分资产减值损失等原因，使得2025年度净利润亏损。 ...

海尔生物发布业绩快报，2025年度公司实现营业总收入23.29亿元，同比增长1.96%；净利润2.51亿元， 同比下降31.61%。2025年公司实现归母净利润2.5亿元，同比下滑31.6%。受外部环境、新建产能爬坡和 公司主动对海外、研发的中长期战略投入影响。 ...

威高骨科发布业绩快报，2025年度营业总收入15.39亿元，同比增长5.95%；净利润2.67亿元，同比增长 19.17%。报告期内，骨科带量采购总体执行平稳，国产头部品牌市场份额持续提升。销售方面，公司 积极进行销售模式和销售组织结构的调整，打造以专业科室为核心维度的事业部利润中心制，推动营销 架构优化升级，激发销售组织活力；进一步细分产品线，通过销售事业部细分管理，提高销售队伍的专 业能力和聚焦度，更精准的进行临床服务和市场学术引领；通过聚焦关键术式的多产线协同销售，核心 重点医院业务增量明显，同时加大下沉市场的开发以及创新产品的推广，整体手术量持续增长，带来收 入和销量的持续增长。 ...

公司继续夯实AI底座，AI+自动化技术体系深度融入样本库、院内用药、细胞培养等应用场景，2025年 公司AI相关收入占公司整体收入比重达15%，较2024年提升2.5个百分点。2025年公司实现归母净利润 2.5亿元，同比下滑31.6%。 格隆汇2月27日丨海尔生物(688139.SH)公布2025年年度业绩快报，2025年公司实现营业收入23.3亿元， 同比增长2.0%，在2024年增长转正的基础上继续提速。第四季度收入同比增速13.1%，内生增长动能持 续强化。2025年公司实现海外收入8.4亿元，同比增长17.9%，占公司主营收入比重再创新高达到36%， 较2024年提升5个百分点；其中欧洲区域增长16.0%，亚太区域增长26.0%，美洲区域增长12.2%，非洲 区域增长17.8%。2025年公司实现国内收入14.7亿元，同比下滑5.5%，自第三季度起环比向好，第四季 度同比增长14.5%，通过拓动销、扩渠道和新模式的持续突破，恢复态势逐渐展现。 报告期内公司毛利率46.8%，主要系子公司新建工厂产能爬坡对制造费用产生扰动所致，随着新产能逐 步释放，第四季度毛利率环比提升约0.7个百分点。净利端承压还与 ...

Group 1 - The medical sector showed strong performance with the largest medical ETF (512170) initially rising over 1% and maintaining positive momentum, outperforming the broader market [1] - Over 1.15 billion CNY of net subscriptions were recorded for the medical ETF, indicating strong investor interest [1] - The ETF has a total scale of 27.7 billion CNY, making it the largest in the medical and healthcare category [3] Group 2 - Huatai Medical reported an expected revenue of 2.584 billion CNY for 2025, representing a year-on-year increase of 25%, with net profit projected at 821 million CNY, up 22% [3] - Other companies within the medical ETF, such as United Imaging and Yirui Technology, are also expected to see net profit growth exceeding 40% [3] - The medical ETF consists of over 50% medical device weight and more than 25% CXO content, covering 12 AI medical and brain-machine interface concept stocks [3] Group 3 - The performance of constituent stocks within the ETF varied, with Huatai Medical leading the gains, rising nearly 7%, while major stocks like Mindray and United Imaging saw declines of nearly 1% [2][3]

（三友医疗公告） 近日，三友医疗发布公告称，2025年度业绩快报显示，公司营业总收入为5.43亿元，同比增长19.66%； 归母净利润为6329万元，同比增加451.85%。 公告中提到，公司业绩增长主要得益于依托创新疗法优势持续开发新产品并深化战略合作，丰富产品线 并推进渠道下沉，有效推动销售业绩稳定增长；同时，公司超声骨刀业务快速扩张，国际化业务实现快 速发展，控股公司Implanet实现营业收入1247万欧元，同比增长32.62%。 ...

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of over 1.15 billion yuan in recent trading sessions [1][5]. Group 1: ETF Performance - The healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1]. - As of February 24, 2026, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year growth of 25%, with a net profit of 821 million yuan, up 22% [3][4]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3]. Group 3: Market Trends - The healthcare sector is characterized by a mix of rising and falling stocks, with Huatai Medical leading gains by rising nearly 7% after a strong earnings report, while major stocks like Mindray and United Imaging saw declines of nearly 1% [1][3].

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of capital [1][8]. Group 1: ETF Performance - On February 27, the healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1][8]. - The ETF saw a net subscription of over 115 million yuan in the previous day, indicating strong investor interest [1][8]. - As of February 24, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5][12]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year increase of 25%, with a net profit of 821 million yuan, up 22% [3][10]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3][10]. - In contrast, Hotgen Biotech is projected to incur a loss of over 200 million yuan [3][10]. Group 3: Stock Movements - Huatai Medical's stock surged over 11% in early trading, currently leading the sector with a nearly 7% increase [4][10]. - Other stocks like Yingke Medical and Meihua Medical also saw gains, while Jinsong Biological experienced a decline of over 2% [4][10].

华夏稳增混合（519029）成立日期2006年8月9日，最新规模13.01亿。今年以来收益22.33%，同类排名 284/8891；近一年收益59.99%，同类排名784/8137；成立以来收益689.64%。 2月27日，麦澜德涨5.05%，截至发稿，报46.37元/股，成交7806.20万元，换手率1.73%，总市值46.37亿 元。 资料显示，南京麦澜德医疗科技股份有限公司位于江苏省南京市雨花台区凤展路32号A2栋，成立日期 2013年1月16日，上市日期2022年8月11日，公司主营业务涉及从事盆底及产后康复领域相关产品的研 发、生产、销售和服务。主营业务收入构成为：盆底康复产品36.98%，生殖康复产品33.10%，耗材及 配件24.32%，运动康复产品2.77%，其他(补充)2.18%，其他产品0.66%。 从麦澜德十大流通股东角度 数据显示，华夏基金旗下1只基金位居麦澜德十大流通股东。华夏稳增混合（519029）三季度减持55.05 万股，持有股数70.15万股，占流通股的比例为1.9%。根据测算，今日浮盈赚取约156.44万元。 华夏稳增混合（519029）基金经理为彭海伟。 截至发稿，彭海伟 ...